Conditions: Parkinson's Disease
Keywords: parkinson's gait dysfunction ampyra 4-aminopyridine
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 22
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in multiple sclerosis. There are multiple studies to suggest that persons with multiple sclerosis benefit from this medication and have major improvements in gait after taking this medication. However, this medication was never studied in Parkinson's disease. This study aims to learn about possible benefits of AMPYRA in Parkinson's disease (PD).

Detailed description:
Subjects with Parkinson's disease will be randomly assigned to two groups. One group will receive Ampyra first for 4 weeks, followed by 2 weeks break and than 4 weeks placebo while the second group will first receive placebo and then Ampyra.

Arms:
arm 1: Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks arm 2: placebo 4 weeks followed by Ampyra 10 mg po BID

Interventions: intervention 1: Ampyra first, then Placebo intervention 2: placebo first, then Ampyra
Intervention descriptions: intervention 1: 10 mg po bid for 4 weeks followed by placebo 4 weeks. intervention 2: placebo

Protocol document: